Abasi Ene Obong (54 gene)
Dr Abasi Ene-Obong is the founder and Chief Executive Officer of 54gene, a health technology company advancing the state of healthcare through large scale discovery and translational research, advanced molecular diagnostics, and clinical programs for the benefit of Africans and the global population.
He holds a PhD in Cancer Biology from University of London, a Masters in human molecular genetics from Imperial College London and a Masters in Business Management from Claremont Colleges, California. He also worked as a cancer researcher and published a seminal paper on pancreatic cancer immunology, Gastroenterology Journal.
He has extensive experience operating in the US, UK and Nigerian healthcare industries. Prior to 54gene, Dr Ene-Obong worked with leading healthcare organisations, including Fortune 100 pharmaceutical companies, academic and research institutions, and governments as a management consultant with PwC and IQVIA (formerly QuintilesIMS).
Founded in 2019, 54gene has made the Time Magazine list of 12 innovations that would change healthcare in the 2020s and has been listed by Nigeria’s Punch newspaper as 1 of 5 innovations that would improve healthcare for Africans. 54gene also made the Fast Company list of the world’s ‘Most Innovative Companies’ in 2020. It was also awarded the best health technology solution by AppsAfrica and Dr. Ene-Obong was listed as 1 of 30 most innovative entrepreneurs on the African continent in 2019 by Quartz Africa. In September 2020, Dr. Ene-Obong was labeled a Nigerian hero in the fight against COVID-19, by a Nigerian newspaper, ThisDay, and also included in Fortune’s 40 under 40 most influential people in healthcare for the year 2020. In the same month, he was selected to join the global Endeavor Entrepreneur Network.